Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: Results from South Australian clinical registry for advanced colorectal cancer

Muhammad A. Khattak, Hilary L. Martin, Carol Beeke, Timothy Price, Scott Carruthers, Susan Kim, Robert Padbury, Christos S. Karapetis

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Colorectal cancer is the third most common cancer in Australia. The median overall survival for metastatic colorectal cancer is nearly 2 years. However, there may be survival differences based on site of metastatic disease. Methods: Data was collected from the South Australian Registry for Advanced Colorectal Cancer. A total of 1207 patients with single site metastatic disease at initial diagnosis were subclassified into 6 subgroups: liver only (n = 780), pelvic only (n = 148), lung only (n = 142), lymph node only (n = 95), bone only (n = 32), and brain only (n = 10). Univariate and multivariate parametric survival analyses were performed. Results: Median overall survival was 20.3 months for the whole group. The overall survival for lung-only metastases group was 41.1 months followed by liver- and pelvic-only disease groups (22.8 and 23.8 months, respectively). Patients with isolated bone-only and brain-only metastases had poor overall survival (5.1 and 5.7 months, respectively). On multivariate analysis, prognosis was superior for the lung-only group. Conclusions: Lung only group had the longest median overall survival. Bone and brain sites had a poor outlook. Site of metastatic disease at initial presentation may be prognostic.

LanguageEnglish
Pages247-254
Number of pages8
JournalClinical Colorectal Cancer
Volume11
Issue number4
DOIs
Publication statusPublished - 1 Dec 2012

Keywords

  • Chemotherapy
  • Colorectal
  • Metastasis
  • Registry
  • Surgery
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Khattak, Muhammad A. ; Martin, Hilary L. ; Beeke, Carol ; Price, Timothy ; Carruthers, Scott ; Kim, Susan ; Padbury, Robert ; Karapetis, Christos S. / Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation : Results from South Australian clinical registry for advanced colorectal cancer. In: Clinical Colorectal Cancer. 2012 ; Vol. 11, No. 4. pp. 247-254.
@article{47636432c4904ada803f37df95f173f7,
title = "Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: Results from South Australian clinical registry for advanced colorectal cancer",
abstract = "Background: Colorectal cancer is the third most common cancer in Australia. The median overall survival for metastatic colorectal cancer is nearly 2 years. However, there may be survival differences based on site of metastatic disease. Methods: Data was collected from the South Australian Registry for Advanced Colorectal Cancer. A total of 1207 patients with single site metastatic disease at initial diagnosis were subclassified into 6 subgroups: liver only (n = 780), pelvic only (n = 148), lung only (n = 142), lymph node only (n = 95), bone only (n = 32), and brain only (n = 10). Univariate and multivariate parametric survival analyses were performed. Results: Median overall survival was 20.3 months for the whole group. The overall survival for lung-only metastases group was 41.1 months followed by liver- and pelvic-only disease groups (22.8 and 23.8 months, respectively). Patients with isolated bone-only and brain-only metastases had poor overall survival (5.1 and 5.7 months, respectively). On multivariate analysis, prognosis was superior for the lung-only group. Conclusions: Lung only group had the longest median overall survival. Bone and brain sites had a poor outlook. Site of metastatic disease at initial presentation may be prognostic.",
keywords = "Chemotherapy, Colorectal, Metastasis, Registry, Surgery, Survival",
author = "Khattak, {Muhammad A.} and Martin, {Hilary L.} and Carol Beeke and Timothy Price and Scott Carruthers and Susan Kim and Robert Padbury and Karapetis, {Christos S.}",
year = "2012",
month = "12",
day = "1",
doi = "10.1016/j.clcc.2012.06.004",
language = "English",
volume = "11",
pages = "247--254",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "4",

}

Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation : Results from South Australian clinical registry for advanced colorectal cancer. / Khattak, Muhammad A.; Martin, Hilary L.; Beeke, Carol; Price, Timothy; Carruthers, Scott; Kim, Susan; Padbury, Robert; Karapetis, Christos S.

In: Clinical Colorectal Cancer, Vol. 11, No. 4, 01.12.2012, p. 247-254.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation

T2 - Clinical Colorectal Cancer

AU - Khattak, Muhammad A.

AU - Martin, Hilary L.

AU - Beeke, Carol

AU - Price, Timothy

AU - Carruthers, Scott

AU - Kim, Susan

AU - Padbury, Robert

AU - Karapetis, Christos S.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Background: Colorectal cancer is the third most common cancer in Australia. The median overall survival for metastatic colorectal cancer is nearly 2 years. However, there may be survival differences based on site of metastatic disease. Methods: Data was collected from the South Australian Registry for Advanced Colorectal Cancer. A total of 1207 patients with single site metastatic disease at initial diagnosis were subclassified into 6 subgroups: liver only (n = 780), pelvic only (n = 148), lung only (n = 142), lymph node only (n = 95), bone only (n = 32), and brain only (n = 10). Univariate and multivariate parametric survival analyses were performed. Results: Median overall survival was 20.3 months for the whole group. The overall survival for lung-only metastases group was 41.1 months followed by liver- and pelvic-only disease groups (22.8 and 23.8 months, respectively). Patients with isolated bone-only and brain-only metastases had poor overall survival (5.1 and 5.7 months, respectively). On multivariate analysis, prognosis was superior for the lung-only group. Conclusions: Lung only group had the longest median overall survival. Bone and brain sites had a poor outlook. Site of metastatic disease at initial presentation may be prognostic.

AB - Background: Colorectal cancer is the third most common cancer in Australia. The median overall survival for metastatic colorectal cancer is nearly 2 years. However, there may be survival differences based on site of metastatic disease. Methods: Data was collected from the South Australian Registry for Advanced Colorectal Cancer. A total of 1207 patients with single site metastatic disease at initial diagnosis were subclassified into 6 subgroups: liver only (n = 780), pelvic only (n = 148), lung only (n = 142), lymph node only (n = 95), bone only (n = 32), and brain only (n = 10). Univariate and multivariate parametric survival analyses were performed. Results: Median overall survival was 20.3 months for the whole group. The overall survival for lung-only metastases group was 41.1 months followed by liver- and pelvic-only disease groups (22.8 and 23.8 months, respectively). Patients with isolated bone-only and brain-only metastases had poor overall survival (5.1 and 5.7 months, respectively). On multivariate analysis, prognosis was superior for the lung-only group. Conclusions: Lung only group had the longest median overall survival. Bone and brain sites had a poor outlook. Site of metastatic disease at initial presentation may be prognostic.

KW - Chemotherapy

KW - Colorectal

KW - Metastasis

KW - Registry

KW - Surgery

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84868111722&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2012.06.004

DO - 10.1016/j.clcc.2012.06.004

M3 - Article

VL - 11

SP - 247

EP - 254

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 4

ER -